Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy:A meta-analysis

Ying Zhang, Xinjun Wang, Guangcheng Luo, Xiaofang Zhou, Ran Xu2023 · DOI

Introduction

Castration-resistant prostate cancer (CRPC) represents an advanced and aggressive stage of the disease where standard androgen deprivation therapies are no longer effective. While docetaxel-based chemotherapy remains a cornerstone of treatment for these patients, clinical responses vary widely. There is a critical clinical need for reliable, accessible biomarkers to predict patient outcomes and guide personalized treatment strategies.

The neutrophil-to-lymphocyte ratio (NLR) has emerged as a potential prognostic indicator. Calculated from a standard complete blood count, the NLR reflects the balance between systemic inflammation (represented by neutrophils) and the host's anti-tumor immune response (represented by lymphocytes). While a high NLR has been associated with poor prognosis in various malignancies, its specific value in CRPC patients treated with docetaxel remains a subject of debate due to inconsistent findings in individual studies. This protocol outlines a systematic meta-analysis designed to provide a definitive assessment of NLR's prognostic utility.

Methodology

This study follows a rigorous systematic review and meta-analysis protocol to synthesize existing evidence from multiple clinical sources.

Search Strategy and Study Selection

The researchers will conduct an exhaustive search of major medical databases, including PubMed, EMBASE, and the Cochrane Library, for relevant studies published up to February 20, 2023. The inclusion criteria encompass retrospective studies, prospective studies, and randomized controlled trials (RCTs) involving CRPC patients undergoing docetaxel-based chemotherapy.

Quality Assessment

To ensure the robustness of the meta-analysis, five independent reviewers will evaluate the quality of the included studies. Non-randomized studies will be assessed using the Newcastle-Ottawa Scale (NOS), a validated tool for identifying potential risks of bias in observational research.

Statistical Analysis

The primary outcomes of interest are Overall Survival (OS) and Progression-Free Survival (PFS). The prognostic impact of NLR will be quantified using pooled Hazard Ratios (HRs) and 95% confidence intervals. The analysis will utilize both fixed-effects and random-effects models to account for inter-study variability. Heterogeneity will be assessed using $I^2$ and $\tau^2$ statistics. Furthermore, sensitivity analyses—conducted by sequentially excluding individual studies—will be performed to ensure the stability of the results.

Discussion and Clinical Implications

The core hypothesis of this research rests on the established link between systemic inflammation and cancer progression. A high NLR typically signifies a pro-inflammatory state that may facilitate tumor growth and suppress effective immune surveillance.

The primary advantage of NLR as a biomarker is its high clinical utility and low cost. Unlike sophisticated genetic sequencing or specialized imaging, NLR is derived from routine blood tests already integrated into standard oncological care. If the meta-analysis confirms its prognostic value, NLR could serve as a widely accessible tool for risk stratification.

To address the "controversy" in existing literature, the authors plan to perform subgroup analyses based on factors such as geographic region, publication year, and specific NLR cutoff values. This approach aims to identify the sources of previous discrepancies and establish more standardized clinical thresholds.

Current Status and Limitations

As this is a protocol, definitive quantitative results are not yet available; the project is currently in the data extraction phase. The final report will provide the pooled HRs necessary to confirm NLR's role in CRPC prognosis.

Potential limitations include the likely predominance of retrospective studies, which are susceptible to selection bias. Additionally, the lack of a universal "cutoff" for what constitutes a high NLR remains a challenge for clinical standardization. Future research will need to focus on integrating validated NLR thresholds into clinical decision-making algorithms and exploring whether therapeutic modulation of the inflammatory environment can improve survival outcomes.

Summary updated

Abstract

Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration
BibTeX
@misc{zhang2023neutrophil,
  author = {Ying Zhang and Xinjun Wang and Guangcheng Luo and Xiaofang Zhou and Ran Xu},
  title = {{Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy:A meta-analysis}},
  year = {2023},
  doi = {10.37766/inplasy2023.3.0018},
}
Figure